Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 4Neoplasms 2Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Oligodendroglioma 1Metastatic Castration-resistant Prostate Cancer 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × cabazitaxel × Clear all
NCT01740570 2018-01-19

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡